Sarepta Therapeutics Inc (NASDAQ:SRPT) – Research analysts at Leerink Swann issued their FY2020 EPS estimates for shares of Sarepta Therapeutics in a research report issued to clients and investors on Thursday. Leerink Swann analyst J. Schwartz forecasts that the biotechnology company will post earnings per share of $2.91 for the year. Leerink Swann has a “Outperform” rating and a $77.00 price target on the stock.
Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, October 25th. The biotechnology company reported ($0.20) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.86) by $0.66. Sarepta Therapeutics had a negative return on equity of 51.72% and a negative net margin of 112.08%. The firm had revenue of $45.95 million during the quarter, compared to the consensus estimate of $41.29 million. During the same period last year, the company earned ($0.95) earnings per share.
Shares of Sarepta Therapeutics (NASDAQ:SRPT) traded up $0.54 during midday trading on Monday, hitting $62.38. The company had a trading volume of 1,227,500 shares, compared to its average volume of 2,112,416. Sarepta Therapeutics has a 52-week low of $26.26 and a 52-week high of $62.96. The company has a current ratio of 10.44, a quick ratio of 9.52 and a debt-to-equity ratio of 0.04. The firm has a market capitalization of $4,230.00, a P/E ratio of -30.58 and a beta of 1.37.
In other news, Director Hans Lennart Rudolf Wigzell sold 6,667 shares of the stock in a transaction on Thursday, November 30th. The shares were sold at an average price of $55.89, for a total value of $372,618.63. Following the completion of the sale, the director now directly owns 13,333 shares of the company’s stock, valued at $745,181.37. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Shamim Ruff sold 10,000 shares of the stock in a transaction on Monday, November 6th. The stock was sold at an average price of $55.00, for a total transaction of $550,000.00. Following the completion of the sale, the senior vice president now directly owns 37,045 shares of the company’s stock, valued at $2,037,475. The disclosure for this sale can be found here. 9.60% of the stock is currently owned by corporate insiders.
Several hedge funds and other institutional investors have recently made changes to their positions in SRPT. Ladenburg Thalmann Financial Services Inc. lifted its holdings in Sarepta Therapeutics by 140.9% in the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 4,262 shares of the biotechnology company’s stock valued at $193,000 after acquiring an additional 2,493 shares during the period. Fox Run Management L.L.C. bought a new position in Sarepta Therapeutics during the 3rd quarter worth $204,000. Ameritas Investment Partners Inc. grew its stake in Sarepta Therapeutics by 6.3% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,561 shares of the biotechnology company’s stock worth $154,000 after buying an additional 271 shares during the last quarter. Cubist Systematic Strategies LLC grew its stake in Sarepta Therapeutics by 116.4% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 4,600 shares of the biotechnology company’s stock worth $155,000 after buying an additional 2,474 shares during the last quarter. Finally, Strs Ohio bought a new position in Sarepta Therapeutics during the 3rd quarter worth $208,000. 81.97% of the stock is owned by hedge funds and other institutional investors.
WARNING: This piece was first published by American Banking News and is the property of of American Banking News. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2018/01/22/sarepta-therapeutics-inc-expected-to-earn-fy2020-earnings-of-2-91-per-share-srpt.html.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.